Quote:

---

and why would we devise a protocol that makes it harder for us on showing efficacy?

---

Our moderate trial is actually for severe patients. Pfizer's trial is actually for moderate patients as can be seen by the inclusion/exclusion criteria. With more moderate patients available it would be much easier for Pfizer to enroll and why there would be a difference in protocols. It's also why the two are not comparable.